Neuroplasticity in Maternal Opioid Use Disorder (OUD)

NARecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Opioid Use Disorder
Interventions
BEHAVIORAL

ERPs with electroencephalography (EEG)

E-Prime 2.0 software will present visual and auditory stimuli in an experimental paradigm lasting approximately 30 minutes (ERPs). Visual stimuli will include photographs of color photographs of unfamiliar infants (aged 5- 10 months) balanced for ethnicity (Black/White) and gender (male/female) displaying happy neutral, and sad affective expressions. Auditory stimuli will include 2-second audio clips of high-distress and low-distress infant cries. Experimental procedure: Trials will consist of a central fixation cross (jittered 400-600ms), stimulus presentation (500ms faces, 2000ms cries), and blank screen (1000ms). Continuous electroencephalography (EEG) will be recorded using Net Station 4.2.1. A 128 Ag/Silver Chloride (AgCl) electrode net will be soaked in a warm potassium chloride solution, and net electrodes will be spaced evenly and symmetrically on each participant's head to cover the scalp.

BEHAVIORAL

MIO

A 12-week, manualized, individual parenting psychotherapy developed specifically for mothers with addictions administered by the Principal Investigator. It is designed to foster a mother's capacity for mentalization or reflective functioning (RF). MIO is offered in conjunction with standard addiction treatment.

Trial Locations (1)

06520

RECRUITING

Yale Child Studies Center, New Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

Yale University

OTHER

NCT05495984 - Neuroplasticity in Maternal Opioid Use Disorder (OUD) | Biotech Hunter | Biotech Hunter